Publication

Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis

British Journal of Pharmacology 181(19):3717-3742, 2024. Gu-Choul Shin, Hyeong Min Lee, Nayeon Kim, Jihyeon Hur, Sang-Ku Yoo, Yun Sun Park, Hyung Soon Park, Dongryeol Ryu, Min-Ho Park, Jung Hee Park, Sang-Uk Seo, Leo Sungwong Choi, Martin Rønn Madsen, Michael Feigh, Kwang Pyo Kim, Kyun-Hwan Kim.

Subjects

Mouse AMLN DIO-MASH mouse Body weight Blood biochemistry Bioinformatics Metabolic dysfunction-associated steatohepatitis Histopathology score Image analysis Immunohistochemistry (IHC)Liver biopsy Liver morphometry Paraoxonase-2 Next-generation sequencing HSG4113 RNA sequencing Semaglutide Vutiglabridin

Share this page

Resource Library

Related resources

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

The selective peroxisome proliferator‐activated receptor gamma modulator CHS‐131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650